Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRDF NASDAQ:FENC NASDAQ:IMMP OTCMKTS:JUSHF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRDFCardiff Oncology$4.12-0.2%$3.36$2.01▼$5.64$274.75M1.521.21 million shs838,205 shsFENCAdherex Technologies$8.71-0.9%$7.93$3.96▼$9.30$242.60M0.3992,442 shs56,480 shsIMMPPrima BioMed$1.63-3.6%$1.79$1.32▼$2.72$246.81M1.71160,008 shs58,277 shsJUSHFJushi$0.41-13.4%$0.33$0.22▼$0.69$92.42M-1.06123,639 shs106,059 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRDFCardiff Oncology-0.24%+4.57%+8.14%+46.62%+64.14%FENCAdherex Technologies-0.91%+0.11%+9.84%+70.78%+33.18%IMMPPrima BioMed-3.55%-4.12%-6.32%+12.41%-20.10%JUSHFJushi-11.81%+19.64%+47.96%+35.63%-33.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRDFCardiff Oncology1.2363 of 5 stars3.40.00.00.02.00.00.6FENCAdherex Technologies2.4576 of 5 stars3.61.00.00.02.93.30.0IMMPPrima BioMed1.5119 of 5 stars3.51.00.00.03.30.00.0JUSHFJushiN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRDFCardiff Oncology 2.83Moderate Buy$11.70183.98% UpsideFENCAdherex Technologies 3.25Buy$13.0049.25% UpsideIMMPPrima BioMed 3.00Buy$7.00329.45% UpsideJUSHFJushi 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest JUSHF, IMMP, CRDF, and FENC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025CRDFCardiff OncologyLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$3.506/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/20/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/14/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.005/9/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRDFCardiff Oncology$680K403.09N/AN/A$1.86 per share2.22FENCAdherex Technologies$30.91M7.78$0.03 per share272.17($0.21) per share-41.48IMMPPrima BioMedN/AN/AN/AN/A$1.05 per shareN/AJUSHFJushi$257.52M0.31N/AN/A($0.26) per share-1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRDFCardiff Oncology-$45.43M-$0.92N/AN/AN/A-8,308.50%-76.45%-62.85%8/14/2025 (Estimated)FENCAdherex Technologies-$440K-$0.51N/AN/AN/A-45.52%N/A-26.37%8/12/2025 (Estimated)IMMPPrima BioMed-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)JUSHFJushi-$48.78M-$0.24N/AN/AN/A-18.54%N/A-10.71%8/6/2025 (Estimated)Latest JUSHF, IMMP, CRDF, and FENC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025FENCAdherex Technologies-$0.06N/AN/AN/A$9.52 millionN/A8/6/2025N/AJUSHFJushi-$0.06N/AN/AN/A$64.67 millionN/A5/13/2025Q1 2025FENCAdherex Technologies-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 million5/8/2025Q1 2025CRDFCardiff Oncology-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million5/8/2025Q1 2025JUSHFJushi-$0.06-$0.09-$0.03-$0.09$66.23 million$63.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRDFCardiff OncologyN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/AJUSHFJushiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRDFCardiff OncologyN/A6.226.22FENCAdherex TechnologiesN/A5.134.97IMMPPrima BioMedN/A18.86N/AJUSHFJushiN/A1.130.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRDFCardiff Oncology16.29%FENCAdherex Technologies55.51%IMMPPrima BioMed2.32%JUSHFJushi21.68%Insider OwnershipCompanyInsider OwnershipCRDFCardiff Oncology7.70%FENCAdherex Technologies10.98%IMMPPrima BioMed3.07%JUSHFJushi21.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableFENCAdherex Technologies1027.60 million24.57 millionOptionableIMMPPrima BioMed2,021146.04 million141.56 millionOptionableJUSHFJushi1,234196.63 million154.04 millionNot OptionableJUSHF, IMMP, CRDF, and FENC HeadlinesRecent News About These CompaniesJUSHF - Jushi Holdings Inc Chart | MorningstarJune 26, 2025 | morningstar.comMJushi (OTCMKTS:JUSHF) Stock Price Down 2.2% - Here's What HappenedJune 24, 2025 | marketbeat.comJushi and Real Housewives Star Stacey Rusch Celebrate Successful Launch of Lifestyle Cannabis ...June 23, 2025 | bakersfield.comBJushi and Real Housewives Star Stacey Rusch Celebrate Successful Launch of Lifestyle Cannabis Brand ‘Shayo’June 23, 2025 | financialpost.comF3 Top Marijuana Stocks If You Plan To Make A Profit In The Cannabis SectorJune 16, 2025 | marijuanastocks.comMJushi Holdings Inc. Announces Voting Results of Annual Shareholders' MeetingJune 3, 2025 | globenewswire.comJushi Holdings Inc. Announces Voting Results of Annual Shareholders’ MeetingJune 3, 2025 | financialpost.comF3 Marijuana Stocks That Make The Cannabis Industry BetterJune 2, 2025 | marijuanastocks.comMJushi Holdings Inc. Earnings Call: Mixed Sentiments and Strategic ExpansionMay 9, 2025 | tipranks.comJushi Holdings Inc. (JUSHF) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comJushi Holdings Inc. (JUSHF) Reports Q1 Loss, Lags Revenue EstimatesMay 8, 2025 | zacks.comJushi Holdings Reports Q1 2025 Financial Results and Expansion PlansMay 8, 2025 | tipranks.comJushi Holdings Inc. Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comJushi Holdings Inc. Updates Call Time to 4:00 p.m. Eastern Time to Report First Quarter 2025 Financial Results on May 8, 2025May 2, 2025 | financialpost.comFJushi Holdings Inc. Updates Call Time to 4:00 p.m. Eastern Time to Report First Quarter 2025 Financial Results on May 8, 2025May 2, 2025 | globenewswire.comEconomic impact of U.S. cannabis industry set to double over next six yearsApril 25, 2025 | msn.comJushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025 | JUSHF Stock NewsApril 23, 2025 | gurufocus.comJushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025 | JUSHF Stock NewsApril 23, 2025 | gurufocus.comJushi Holdings Inc. to Report First Quarter 2025 Financial Results on May 8, 2025April 23, 2025 | globenewswire.comJushi Holdings Expands Ohio Presence with New Mansfield DispensaryApril 18, 2025 | tipranks.comJushi Holdings Inc. Announces Grand Opening of Beyond Hello™ Mansfield in Ohio, Expanding Its Statewide Retail FootprintApril 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJUSHF, IMMP, CRDF, and FENC Company DescriptionsCardiff Oncology NASDAQ:CRDF$4.12 -0.01 (-0.24%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$4.12 +0.00 (+0.12%) As of 07/15/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Adherex Technologies NASDAQ:FENC$8.71 -0.08 (-0.91%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$8.72 +0.01 (+0.11%) As of 07/15/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Prima BioMed NASDAQ:IMMP$1.63 -0.06 (-3.55%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.61%) As of 07/15/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Jushi OTCMKTS:JUSHF$0.41 -0.06 (-13.43%) As of 07/15/2025 03:59 PM EasternJushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
